Obstructive sleep apnea in USA is expected to rise from 34·3% in 2020 to 46·2%, resulting in 76·6 million OSA cases by 2050. By 2050 there will be more males w/ OSA (~46 milliion) than females (30·4 million), but greater growth in females over the next 30 years. https://t.co/6YZvSusTWf

Multimorbidity predicts flares in rheumatoid arthritis A study from Olmstead county and the Mayo Clinic shows that multimorbidity and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates. https://t.co/yGrvDttcEq https://t.co/45LMtvsFor

• Multimorbidity predicts flares in rheumatoid arthritis | RheumNow

September to Remember (9.5.2025) Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD. https://t.co/dPdweMaJuN https://t.co/aExU5kV26Q

• September to Remember (9.5.2025) | RheumNow

Based on a survey in Japan, resolution of dry mouth was the most important symptom resolution reported by SJD pts. The JCR CPG for SjD suggests RTX for glandular involvement while BEL for extra-glandular involvements. #APLAR25 @RheumNow https://t.co/SsUvQIM9Eu

• https://x.com/RHEUMarampa/status/1963826060845322413/photo/1
• https://x.com/RHEUMarampa/status/1963826060845322413/photo/1

Is it D2T RA or Clinical inertia? Concept introduced by Dr Kaneko, Japanese Keio RA cohort, followed for 5yrs 5% patients not fitting the D2T RA definition have MDA or HDA The drivers of persistent DA in RA: -overestimation of treatment effectiveness -avoidance of treatment https://t.co/0pkDaUFH4R

• https://x.com/AurelieRheumo/status/1963820075947081788/photo/1

Interesting data shared by Dr. Sandhya Pulukool on Asian pts with SjD vs. Caucasians: - Younger age of onset except in Japan - Higher female to male ratio @RheumNow #APLAR25 https://t.co/RPM9zI4tVQ

• https://x.com/RHEUMarampa/status/1963822089582023024/photo/1

Peter Taylor on Pre-RA: If Pre-RA is too late for interception, shall we start screening general population? We have to remember RA is a RARE disease Pre-test of RA per year per person would be 0.00025% for primary prevention: A needle in a haystack? @RheumNow @APLAR_org https://t.co/LKGtz1P7sl

• https://x.com/AurelieRheumo/status/1963813511152463960/photo/1

Peter Taylor describing the range of potential benefits of Interception strategies in Pre-RA: A) From Ideal: full interception B) To Good outcome: stratified intervention based on high risk population for delay/interception C) To ?Beneficial: attenuate severity of established RA https://t.co/6mqA9tV7ME

• https://x.com/AurelieRheumo/status/1963808528394793215/photo/1

Prof Takeuchi on DMARDs treatment and regional disparities For similar dose, serum concentration of the polyglutamate (active) form of MTX is much higher in Japanese than US patients And also high levels achieved much quicker in Japanese than US patients This is strong https://t.co/ikp63wWifj

• https://x.com/AurelieRheumo/status/1963783418917052503/photo/1

What’s new in RA Pathogenesis in #APLAR25 by Ellen Gravellese Take home message: there is still hope for synovial biopsies to be a biomarker for prediction of response to treatment As a synovial biopsy expert, I am not convinced of this one, but time will tell @APLAR_org https://t.co/EEw5ncKa1r

• https://x.com/AurelieRheumo/status/1963776720307425291/photo/1

Can we prevent #rheumatoidarthritis? Dr. Gravallese shares this interesting slide that summarizes the different disease prevention trials in RA…..they have managed to delay disease onset but prevention is still in question. @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/qhGYnNL5Ek

• https://x.com/RHEUMarampa/status/1963776657229283718/photo/1

📍Smoking, obesity and low Vit D are significant risk factors for Pre-RA. 📍Subdoligranulum arthritogenic strain is a newly described infectious agent implicated in the pathogenesis of pre-RA @RheumNow #ACR25 @rheumarhyme https://t.co/ZzZZlfdKmk

• https://x.com/RHEUMarampa/status/1963772715351114060/photo/1